P. Molyneaux (London, United Kingdom), S. Guler (Bern, Switzerland), P. Spagnolo (Padova (PD), Italy), C. Neurohr (München, Germany)
Validation of the IPF-specific version of St. George’s Respiratory Questionnaire in Danish
T. Skovhus Prior (Aarhus, Denmark), N. Hoyer (Hellerup, Denmark), S. Shaker (Hellerup, Denmark), J. Rømhild Davidsen (Odense, Denmark), J. Yorke (Manchester, United Kingdom), O. Hilberg (Vejle, Denmark), E. Bendstrup (Aarhus, Denmark)
|   |
Galactomannans in bronchoalveolar lavage of patients with Idiopathic Pulmonary Fibrosis (IPF): a possible marker of disease progression.
F. Cavalli (Rome, Italy), E. Puxeddu (Rome, Italy), G. Croce (Rome, Italy), G. Pezzuto (Rome, Italy), P. Rogliani (Rome, Italy)
| |
Lung biopsy in patients with suspected idiopathic pulmonary fibrosis and probable interstitial pneumonia on the CT scan.
L. Ramon Clar (Palma, Spain), M. Luna Lopez (Palma, Spain), B. Núñez Sánchez (Palma, Spain), E. Sala Llinàs (Palma, Spain), C. Oliver Terrassa (Palma, Spain), J. Palmer Sancho (Palma, Spain), C. Gomez Bellvert (Palma, Spain), A. Carvajal Carrasco (Palma, Spain), J. Sauleda Roig (Palma, Spain)
| |
Temporal changes in mediastinal lymphadenopathy in patients with idiopathic pulmonary fibrosis
K. Pontoppidan (Southampton, United Kingdom), K. Vedwan (Southampton, United Kingdom), S. Battison (Southampton, United Kingdom), C. Brereton (Southampton, United Kingdom), T. Wallis (Southampton, United Kingdom), M. Jones (Southampton, United Kingdom), S. Fletcher (Southampton, United Kingdom)
| |
Correlations between specific radiological patterns and survival in idiopathic pulmonary fibrosis
M. Mononen (Kuopio, Finland), H. Kettunen (Kuopio, Finland), S. Suoranta (Kuopio, Finland), M. Kärkkäinen (Kuopio, Finland), T. Selander (Kuopio, Finland), M. Purokivi (Kuopio, Finland), R. Kaarteenaho (Oulu, Finland)
| |
Impact of a Bayesian approach on the diagnosis of Interstitial Lung Diseases
V. Tan (SingaporeS, Singapore), S. Tay (SingaporeS, Singapore), F. Teo (SingaporeS, Singapore), P. Quah (SingaporeS, Singapore), L. Teo (SingaporeS, Singapore), C. Ong (SingaporeS, Singapore), J. Seet (SingaporeS, Singapore), T. Lim (SingaporeS, Singapore)
| |
Evaluation of CD163 expression on alveolar macrophages from BAL of patients with Fibrotic Lung Diseases.
E. Vasarmidi (Heraklion, Greece), E. Bibaki (Heraklion, Greece), C. Koutoulaki (Heraklion, Greece), S. Mastrodemou (Heraklion, Greece), A. Trachalaki (Heraklion, Greece), N. Tzanakis (Heraklion, Greece), E. Tsitoura (Heraklion, Greece), K. Antoniou (Heraklion, Greece)
| |
Plasma levels of circulating cell-free DNA are increased in idiopathic pulmonary fibrosis but do not correlate with disease severity
M. Bocchino (Naples, Italy), U. Malpelle (Naples, Italy), D. Galati (Naples, Italy), S. Zanotta (Naples, Italy), F. Pepe (Naples, Italy), P. Pallante (Naples, Italy)
| |
The role of lung ultrasonography in the assessment of idiopathic pulmonary fibrosis –correlation with HRCT finding
M. Man (cluj Napoca, Romania), B. Domokos Gergely (Cluj Napoca, Romania), A. Lesan (Cluj Napoca, Romania), D. Todea (Cluj Napoca, Romania), C. Pop (Cluj Napoca, Romania), N. Motoc (Cluj Napoca, Romania)
| |
Serum KL-6 as a biomarker for interstitial lung diseases in a clinical setting: application of a fully automated immunoassay.
F. Bonella (Essen, Germany), B. Hegedues (Essen, Germany), S. Langer (Gent, Belgium), F. Honshoven (Gent, Belgium), E. Gottstein (Essen, Germany), D. Theegarten (Essen, Germany), U. Costabel (Essen, Germany)
| |
Systemic and local expression of Mithocondrial DNA and Periostin in IPF
P. Soccio (Foggia, Italy), D. Lacedonia (Foggia, Italy), G. Carpagnano (Foggia, Italy), G. Palladino (Foggia, Italy), C. Incoronata (Foggia, Italy), F. Simone (Foggia, Italy), R. Termine (Foggia, Italy), S. Stornelli (Foggia, Italy), M. Foschino-Barbaro (Foggia, Italy)
| |
The Latin American Idiopathic Pulmonary Fibrosis Registry (REFIPI): Baseline Characteristics
I. Buendia Roldán (Mexico, Mexico), F. Caro (Buenos Aires, Argentina), P. Curbelo (Montevideo, Uruguay), R. Kairalla (Sao Paulo, Brazil), M. Mejia (Mexico, Mexico), L. Noriega (Panama, Panama), F. Paulin (Buenos Aires, Argentina), A. Undurraga (Santiago, Chile), M. Selman (Mexico, Mexico), O. Refipi Group (Montevideo, Uruguay)
| |
Dehydroepiandrosterone sulfate plasma levels correlate with lung function in patients with fibrotic interstitial lung disease in two independent cohorts.
S. Guler (Bern, Switzerland), M. Funke-Chambour (Bern, Switzerland), B. Tan (Vancouver, Canada), P. Wilcox (Vancouver, Canada), J. Leung (Vancouver, Canada), T. Geiser (Bern, Switzerland), C. Ryerson (Vancouver, Canada)
| |
Lactate dehydrogenase as a biomarker of advanced disease in idiopathic pulmonary fibrosis
E. Åttingsberg (Hellerup, Denmark), N. Hoyer (Hellerup, Denmark), T. Wilcke (Hellerup, Denmark), T. Prior (Aarhus, Denmark), E. Bendstrup (Aarhus, Denmark), S. Shaker (Hellerup, Denmark)
| |
Serum osteoprotegerin and fibulin-1 levels negatively correlate with DLCO in IPF
H. Habibie (Groningen, Netherlands), J. Burgess (Groningen, Netherlands), M. Wisman (Groningen, Netherlands), M. Jonker (Groningen, Netherlands), M. Kool (Rotterdam, Netherlands), M. Wijsenbeek (Rotterdam, Netherlands), N. Kahn (Heidelberg, Germany), M. Kreuter (Heidelberg, Germany), B. Melgert (Groningen, Netherlands)
| |
Spirometric evaluation of idiopathic pulmonary fibrosis (IPF): forced or slow vital capacity?
J. Rodríguez Moncalvo (Buenos Aires, Argentina), J. Malet Ruiz (Buenos Aires, Argentina), M. Mastroianni (Buenos Aires, Argentina), M. Khoury (Buenos Aires, Argentina), F. Caro (Buenos Aires, Argentina)
| |
Change in serum surfactant protein (SP)-A, SP-D and KL-6 predict the therapeutic effect of antifibrotic drugs in IPF.
T. Yoshikawa (Sapporo, Japan), M. Otsuka (Sapporo, Japan), K. Ikeda (Sapporo, Japan), Y. Mori (Sapporo, Japan), Y. Umeda (Sapporo, Japan), H. Nishikiori (Sapporo, Japan), S. Miyajima (Sapporo, Japan), M. Takahashi (Sapporo, Japan), K. Kuronuma (Sapporo, Japan), H. Chiba (Sapporo, Japan), H. Takahashi (Sapporo, Japan)
| |
Distinct profiles of Th1 and Th2 cytokines in patients with IPF, CTD-ILD, and IPAF
M. Kameda (sapporo, Japan), M. Otsuka (sapporo, Japan), T. Hasegawa (Kobe, Japan), T. Yoshikawa (sapporo, Japan), T. Kobayashi (sapporo, Japan), Y. Umeda (sapporo, Japan), M. Yoshida (Kobe, Japan), T. Kondo (Kobe, Japan), T. Aritsu (Kobe, Japan), K. Kuronuma (sapporo, Japan), H. Chiba (sapporo, Japan), H. Takahashi (sapporo, Japan)
| |
Matrix metalloproteinases, as markers of the severity of idiopathic pulmonary fibrosis
K. Gashynova (Dnipro, Ukraine), V. Rodionova (Dnipro, Ukraine), O. Karasyova (Dnipro, Ukraine), O. Shaulska (Dnipro, Ukraine), O. Khmel (Dnipro, Ukraine)
| |